DK3802570T3 - Forbedrede viruslignende nanopartikler til oral indgivelse - Google Patents

Forbedrede viruslignende nanopartikler til oral indgivelse Download PDF

Info

Publication number
DK3802570T3
DK3802570T3 DK19815509.5T DK19815509T DK3802570T3 DK 3802570 T3 DK3802570 T3 DK 3802570T3 DK 19815509 T DK19815509 T DK 19815509T DK 3802570 T3 DK3802570 T3 DK 3802570T3
Authority
DK
Denmark
Prior art keywords
nanoparticles
oral administration
improved virus
virus
improved
Prior art date
Application number
DK19815509.5T
Other languages
English (en)
Inventor
R Holland Cheng
Chun Chieh Chen
Mohammad Ali Baikoghli
Marie Stark
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK3802570T3 publication Critical patent/DK3802570T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
DK19815509.5T 2018-06-06 2019-06-06 Forbedrede viruslignende nanopartikler til oral indgivelse DK3802570T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862681637P 2018-06-06 2018-06-06
PCT/US2019/035823 WO2019236870A1 (en) 2018-06-06 2019-06-06 Improved virus-like nanoparticles for oral delivery

Publications (1)

Publication Number Publication Date
DK3802570T3 true DK3802570T3 (da) 2024-01-15

Family

ID=68770634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19815509.5T DK3802570T3 (da) 2018-06-06 2019-06-06 Forbedrede viruslignende nanopartikler til oral indgivelse

Country Status (7)

Country Link
US (2) US11466055B2 (da)
EP (1) EP3802570B1 (da)
CN (1) CN112218879A (da)
DK (1) DK3802570T3 (da)
PL (1) PL3802570T3 (da)
PT (1) PT3802570T (da)
WO (1) WO2019236870A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245160A1 (en) * 2022-06-16 2023-12-21 Astrid Pharma Corp. Methods and compositions of quaternary immunomodulatory nanoparticles for medical applications and immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
EP1785433A4 (en) 2004-07-01 2008-10-01 Tokyo Inst Tech VIRUS PARTICULAR CONSTRUCT AND METHOD FOR THEIR EDUCATION UNDER PHYSIOLOGICAL CONDITIONS
KR101032922B1 (ko) * 2008-12-24 2011-05-06 연세대학교 산학협력단 안정화된 다중 알파-헬릭스를 갖는 나노구조체, 상기 나노구조체를 형성하는 고리형 자기조립 화합물, 및 이의 제조 방법
JP5869885B2 (ja) * 2009-02-27 2016-02-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｅ型肝炎ウイルス様粒子を用いた多抗原送達系
US8906863B2 (en) * 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
US8906862B2 (en) * 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
EP3539568A1 (en) * 2011-11-22 2019-09-18 The Children's Hospital of Philadelphia Virus vectors for highly efficient transgene delivery
US8580731B2 (en) * 2012-02-17 2013-11-12 National Taiwan University Insulin-gold nanocluster, pharmaceutical composition for reducing blood glucose comprising the same, and method for detecting adipose cells in tissue by using the same
EP3145540B1 (en) * 2014-05-19 2020-01-29 The Regents of The University of California Chemically activated nanocapsid functionalized for cancer targeting
EP3765074A4 (en) * 2018-03-13 2021-12-29 The Regents of The University of California Virus-like nanocapsid for oral delivery of insulin

Also Published As

Publication number Publication date
EP3802570A1 (en) 2021-04-14
US20210221850A1 (en) 2021-07-22
WO2019236870A1 (en) 2019-12-12
US20230159596A1 (en) 2023-05-25
PT3802570T (pt) 2024-01-15
EP3802570A4 (en) 2022-03-16
EP3802570B1 (en) 2023-10-18
CN112218879A (zh) 2021-01-12
US11466055B2 (en) 2022-10-11
PL3802570T3 (pl) 2024-03-18
WO2019236870A9 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3634468T3 (da) Fast sammensætning til oral indgivelse
MA50541A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
HUP1700253A1 (hu) Szilárd orális gyógyszerkészítmények
MA46867A (fr) Formulations pharmaceutiques
DK3229816T3 (en) Proton-bindende polymerer til oral administration
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
FR3027521B1 (fr) Compositions pour administration par voie orale
DK3762009T3 (da) Toxin-afledte indgivelseskonstrukter til oral indgivelse
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
DK3244920T3 (da) Mund- og klovsyge-vaccine
DK2964193T3 (da) Lægemidler til oral indgivelse
PT3157506T (pt) Composição farmacêutica oral com sabor mascarado
DK3436120T3 (da) Oral medicinsk indretning
HK1251470A1 (zh) 口腔護理組合物
HK1245646A1 (zh) 口服給藥用醫藥組合物
DK3802570T3 (da) Forbedrede viruslignende nanopartikler til oral indgivelse
IT201600129110A1 (it) Manipolo per endodonzia
IT201600129093A1 (it) Manipolo per endodonzia
HK1232144A1 (zh) 經口給藥用醫藥組合物
DK2952207T3 (da) Oliebaserede farmaceutiske sammensætninger til oral indgivelse
IT201700090397A1 (it) Siringa per odontoiatria
BR112017004882A2 (pt) composição farmacêutica oral.
TH1501007612A (th) อมอร์ฟัสลีเทอร์โมเวียร์และสูตรผสมของแข็งทางเภสัชกรรมของมันสำหรับให้เข้าทางปาก